scholarly journals KS-3　Development of Perioperative Glycemic Control Using an Artificial Pancreas and Surgical Diabetes Treatment

2018 ◽  
Vol 52 (3) ◽  
pp. 57-57
Author(s):  
Kazuhiro Hanazaki ◽  
Sunao Uemura ◽  
Masaya Munekage ◽  
Kazune Fujisawa ◽  
Sachi Tsuda ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Artificial Pancreas ◽  
Diabetes Treatment ◽  
Surgical Diabetes

Insulin, glucagon, and amino acids during glycemic control by the artificial pancreas in diabetic man

Metabolism ◽  
1980 ◽  
Vol 29 (4) ◽  
pp. 321-332 ◽  
Author(s):  
Amir K. Hanna ◽  
Bernard Zinman ◽  
Azima F. Nakhooda ◽  
Howard L. Minuk ◽  
Elaine F. Stokes ◽  
...  
Keyword(s):  
Amino Acids ◽  
Glycemic Control ◽  
Artificial Pancreas

Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

2021 ◽  
Author(s):  
Coralie Amadou ◽  
Sylvia Franc ◽  
Pierre-Yves Benhamou ◽  
Sandrine Lablanche ◽  
Erik Huneker ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Adverse Events ◽  
Closed Loop ◽  
Artificial Pancreas ◽  
Real Life ◽  
Serious Adverse Events ◽  
Life Conditions ◽  
Time In Range

<b>OBJECTIVE </b> <p>To analyze safety and efficacy of the DBLG1 hybrid closed-loop artificial pancreas system in patients with Type 1 Diabetes in real life conditions. </p> <p> </p> <p><b>METHODS</b></p> <p>Following a one-week run-in period with usual pump, 25 patients were provided with the commercial DBLG1 system. We present the results of Time-in-Range and HbA1c over a 6-month period.</p> <p><b> </b></p> <p><b>RESULTS</b></p> <p>The mean (SD;range) age of patients was 43 years (13.8; 25-72). At baseline, mean HbA1c and TIR 70-180mg/dL were respectively 7.9% (0.93; 5.6- 8.5) [63mmol/mol (10; 38-69)] and 53% (16.4;21-85). One patient stopped using the system after 2 months. At 6-month, mean HbA1c decreased to 7.1% [54mmol/mol] (p<0.001) and TIR 70-180mg/dL increased to 69.7% (p<0.0001). TIR<70mg/dL decreased from 2.4 to 1.3% (p=0.03). TIR<54mg/dL decreased from 0.32 to 0.24% (p=0.42). No serious adverse event was reported during the study. </p> <p> </p> <p><b>CONCLUSION</b></p> <p>The DBLG1 System confirms its ability to significantly improve glycemic control in real life conditions, without serious adverse events. </p>

scholarly journals Use of a do-it-yourself artificial pancreas system is associated with better glucose management and higher quality of life among adults with type 1 diabetes

2020 ◽  
Vol 11 ◽  
pp. 204201882095014
Author(s):  
Zekai Wu ◽  
Sihui Luo ◽  
Xueying Zheng ◽  
Yan Bi ◽  
Wen Xu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Artificial Pancreas ◽  
Pump Therapy ◽  
Quality Of Life Scale ◽  
Do It Yourself ◽  
Glucose Management

Background: Previous studies show that the use of do-it-yourself artificial pancreas system (DIYAPS) may be associated with better glycemic control characterized by improved estimated hemoglobin A1c (eHbA1c) and time in range among adults with type 1 diabetes (T1D). However, few studies have demonstrated the changes in laboratory-measured HbA1c, which is a more accepted index for glycemic control, after using a DIYAPS. Methods: This is a retrospective before-after study approaching patients who reported self-use of AndroidAPS. The main inclusion criteria included: T1D; aged ⩾18 years; having complete record of ⩾3 months of continuous AndroidAPS use; with laboratory-measured HbA1c and quality of life scale data before and after 3 months of AndroidAPS use; and not pregnant. The primary outcome was the change in HbA1c between baseline and 3 months after initiation of AndroidAPS use. Results: Overall, 15 patients (10 females) were included; the median age was 32.2 years (range: 19.2–69.4), median diabetes duration was 9.7 years (range: 1.8–23.7) and median baseline HbA1c was 7.3% (range: 6.4–10.1). The 3 months of AndroidAPS use was associated with substantial reductions in HbA1c [6.79% (SD: 1.29) versus 7.63% (SD: 1.06), p = 0.002] and glycemic variability when compared with sensor-augmented pump therapy. A lower level of fear of hypoglycemia [22.13 points (SD: 6.87) versus 26.27 points (SD: 5.82), p = 0.010] was also observed after using AndroidAPS. Conclusions: The 3 months of AndroidAPS use was associated with significant improvements in glucose management and quality of life among adults with T1D.

scholarly journals Use of a Meter With Color-Range Indicators and a Mobile Diabetes Management App Improved Glycemic Control and Patient Satisfaction in an Underserved Hispanic Population: “Tu Salud”—a Randomized Controlled Partial Cross-Over Clinical Study

2021 ◽  
Author(s):  
Maria Aparicio ◽  
Laurence B. Katz ◽  
Hilary Cameron ◽  
Frederico Ceppa
Keyword(s):  
Glycemic Control ◽  
Treatment Satisfaction ◽  
Diabetes Management ◽  
Mobile App ◽  
Spanish Language ◽  
Control Group ◽  
Hispanic Population ◽  
Diabetes Treatment ◽  
Language Version ◽  
Control Subjects

To demonstrate the clinical value of OneTouch (OT) Verio Flex glucose meter used in combination with a Spanish-language version of the OT Reveal mobile application (app) to support diabetes care and improve glycemic control in an underserved Hispanic population with type 2 diabetes. Test subjects (<i>n </i>= 81) used the meter and app for 12 weeks, while a randomized control group (<i>n </i>= 39) used their own glucose meters without connection to an app. Thereafter, test subjects continued the same regimen for an additional 12 weeks to determine the durability of effect, and control subjects crossed over to use the new meter and app.<b> </b>Test subjects experienced a mean reduction in A1C of 1.0% after 12 weeks (<i>P </i><0.001), a statistically significant greater reduction than in control subjects (<i>P </i>= 0.045). The improvement in A1C in test subjects was sustained over the next 12 weeks. Crossed-over subjects also demonstrated significant improvements in A1C (<i>P </i><0.001). Mean blood glucose was reduced significantly without an increase in hypoglycemia and results in range increased over 12 weeks of meter and mobile app use. Results were independent of subjects’ numeracy skills. Subjects using the new meter and app reacted favorably to the tools and expressed improvements in their diabetes treatment satisfaction based on Diabetes Treatment Satisfaction Questionnaire–Change scores. Use of the OT meter and a Spanish-language version of its diabetes management app in an underserved population helped participants achieve a sustained improvement in glycemic control. The tools were well received by the subjects and may have important utility in other low-numeracy, low-literacy populations. <div><br></div>

scholarly journals Use of a Meter With Color-Range Indicators and a Mobile Diabetes Management App Improved Glycemic Control and Patient Satisfaction in an Underserved Hispanic Population: “Tu Salud”—a Randomized Controlled Partial Cross-Over Clinical Study

2021 ◽  
Author(s):  
Maria Aparicio ◽  
Laurence B. Katz ◽  
Hilary Cameron ◽  
Frederico Ceppa
Keyword(s):  
Glycemic Control ◽  
Treatment Satisfaction ◽  
Diabetes Management ◽  
Mobile App ◽  
Spanish Language ◽  
Control Group ◽  
Hispanic Population ◽  
Diabetes Treatment ◽  
Language Version ◽  
Control Subjects

To demonstrate the clinical value of OneTouch (OT) Verio Flex glucose meter used in combination with a Spanish-language version of the OT Reveal mobile application (app) to support diabetes care and improve glycemic control in an underserved Hispanic population with type 2 diabetes. Test subjects (<i>n </i>= 81) used the meter and app for 12 weeks, while a randomized control group (<i>n </i>= 39) used their own glucose meters without connection to an app. Thereafter, test subjects continued the same regimen for an additional 12 weeks to determine the durability of effect, and control subjects crossed over to use the new meter and app.<b> </b>Test subjects experienced a mean reduction in A1C of 1.0% after 12 weeks (<i>P </i><0.001), a statistically significant greater reduction than in control subjects (<i>P </i>= 0.045). The improvement in A1C in test subjects was sustained over the next 12 weeks. Crossed-over subjects also demonstrated significant improvements in A1C (<i>P </i><0.001). Mean blood glucose was reduced significantly without an increase in hypoglycemia and results in range increased over 12 weeks of meter and mobile app use. Results were independent of subjects’ numeracy skills. Subjects using the new meter and app reacted favorably to the tools and expressed improvements in their diabetes treatment satisfaction based on Diabetes Treatment Satisfaction Questionnaire–Change scores. Use of the OT meter and a Spanish-language version of its diabetes management app in an underserved population helped participants achieve a sustained improvement in glycemic control. The tools were well received by the subjects and may have important utility in other low-numeracy, low-literacy populations. <div><br></div>

scholarly journals Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence

2021 ◽  
Vol 45 (6) ◽  
pp. 813-839
Author(s):  
Sun Joon Moon ◽  
Inha Jung ◽  
Cheol-Young Park
Keyword(s):  
Glycemic Control ◽  
Clinical Evidence ◽  
Rapid Development ◽  
Artificial Pancreas ◽  
Glucose Monitoring ◽  
Dose Titration ◽  
Paradigm Shifts ◽  
Current State ◽  
Technological Advances

Since Banting and Best isolated insulin in the 1920s, dramatic progress has been made in the treatment of type 1 diabetes mellitus (T1DM). However, dose titration and timely injection to maintain optimal glycemic control are often challenging for T1DM patients and their families because they require frequent blood glucose checks. In recent years, technological advances in insulin pumps and continuous glucose monitoring systems have created paradigm shifts in T1DM care that are being extended to develop artificial pancreas systems (APSs). Numerous studies that demonstrate the superiority of glycemic control offered by APSs over those offered by conventional treatment are still being published, and rapid commercialization and use in actual practice have already begun. Given this rapid development, keeping up with the latest knowledge in an organized way is confusing for both patients and medical staff. Herein, we explore the history, clinical evidence, and current state of APSs, focusing on various development groups and the commercialization status. We also discuss APS development in groups outside the usual T1DM patients and the administration of adjunct agents, such as amylin analogues, in APSs.

scholarly journals Effect of 6 months flash glucose monitoring in youth with type 1 diabetes and high-risk glycemic control – a randomized controlled trial

2020 ◽  
Author(s):  
Sara E Boucher ◽  
Andrew R Gray ◽  
Esko J Wiltshire ◽  
Martin I de Bock ◽  
Barbara C Galland ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
High Risk ◽  
Glycemic Control ◽  
Treatment Satisfaction ◽  
Glucose Monitoring ◽  
Diabetes Treatment ◽  
Glucose Testing ◽  
Randomized Controlled ◽  
Freestyle Libre

OBJECTIVE <p>To investigate whether intermittently scanned continuous glucose monitoring (isCGM) significantly improves glycemic control compared with capillary self-monitored blood glucose (SMBG) in youth with type 1 diabetes and high-risk glycemic control.</p> <p>RESEARCH DESIGN AND METHODS</p> <p>This multi-center 6-month randomized, controlled, parallel-arm trial included 64 participants aged 13 to 20 years with established Type 1 diabetes and glycated hemoglobin (HbA1c) ≥9% (≥75mmol/mol). Participants were allocated to 6-month intervention (isCGM, FreeStyle Libre, Abbott; n = 33) or control (SMBG; n = 31) using minimization. The primary outcome was the difference in change in HbA1c from baseline to 6 months. </p> <p>RESULTS</p> <p>There was no evidence of a difference between groups for changes in HbA1c at 6 months (adjusted mean 0.2% greater improvement for isCGM, 95% CI -0.9% to 0.5% [-2.1 mmol/mol, 95% CI -9.6 to 5.4], p = 0.576). However, glucose monitoring frequency was 2.83 (95% CI 1.72 to 4.65, p < 0.001) times higher in the isCGM group compared to that in the SMBG group at 6 months. The change in the Diabetes Treatment Satisfaction Questionnaire mean item score also favored isCGM at 6 months (p=0.048), with no significant differences between groups for fear of hypoglycemia and quality of life (both general and diabetes-specific) all p>0.1.</p> <p>CONCLUSIONS</p> <p>For youth with high-risk glycemic control, isCGM led to improvements in glucose testing frequency and diabetes treatment satisfaction. However, these did not translate to greater improvement in glycemic control over usual care with SMBG at 6 months. </p>

scholarly journals Acute worsening of glycemic control in a patient with type 2 diabetes and non-small cell lung cancer after administration of lorlatinib

2021 ◽  
Author(s):  
Yoshio NAKANO ◽  
Mai MIYASATO-ISODA ◽  
Iwao GHOMA ◽  
Tomomi FUJISAWA
Keyword(s):  
Lung Cancer ◽  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Glucose Monitoring ◽  
Small Cell ◽  
Diabetes Treatment ◽  
Small Cell Lung

A case with non-small cell lung cancer exhibited extreme hyperglycemia after lorlatinib treatment, whose adverse effects on hyperglycemia is little known. But, the lorlatinib could be continued by intensifying diabetes treatment, indicating the importance of glucose monitoring during lorlatinib administration, and of adequate intensification of treatment for such hyperglycemia.

Sign in / Sign up

Export Citation Format

Share Document